Proteomics & Metabolomics
In addition to doing work on existing IGBB projects, the IGBB proteomics staff can
perform a variety of mass spectrometry and other proteomics services for MS State principal investigators and
IGBB collaborators. Such research can be performed through a Proposal Partnership,
a Research Agreement, or the Service Center.
The
IGBB's proteomics staff has considerable expertise in...
- Protein isolation/purification from all types of organisms/tissues
- 1D & 2D gel electrophoresis
- Gel- and non-gel-based mass spectrometry
- Protein identification
- Discovery and characterization of post-translational modifications;
- Quantitative proteomics
- Comparative proteomics & metabolomics
- Western blotting & protein visualization
- Integration of proteomic and nucleic acids data (e.g., proteogenomic
mapping)
- Functional annotation of proteins using Gene Ontology (GO)
standards and procedures
With regard to mass spectrometers, the IGBB's proteomics staff utilizes a ThermoFisher LTQ Orbitrap Velos, a Waters Nano ESI Q-TOF (model Xevo G2-S), and an Applied Biosystems (now ThermoFisher) MALDI TOF TOF. The LTQ Orbitrap Velos and the Nano ESI Q-TOF are fitted with upstream HPLC sample
purification systems.
To discuss the possibility of having the IGBB conduct
proteomics research in collaboration with you, please submit a ticket through the MyIGBB HelpDesk.
An IGBB proteomics consultant will respond to your query as quickly as possible
(usually within 24 hours).
A listing of IGBB Standard Services and their prices -- including information and prices for Training and Self-Service Equipment Usage -- is available in the Standard Services Catalog in MyIGBB and in PDF form via the link below.
ALSO SEE: Genomics (including Transcriptomics) | Biocomputing (Bioinformatics & Computational Biology)
NOTE: PIs are asked to consider whether the participation of an IGBB employee in a project merits that employee's inclusion as a co-author on a resulting manuscript(s). The decision ultimately lies with the PI. However, the IGBB encourages IGBB staff and faculty involved in
Proposal Partnerships and
Research Agreements to discuss/negotiate co-authorship with PIs before starting work on a project.
Michelle LathamBusiness Coordinator
PURCHASING
email(662) 325-4075
Current perspectives on the use of alternative species in human health and ecological hazard assessments
IGBB Authors:
Natàlia Garcia-ReyeroPUBLICATION YEAR:
2013IMPACT FACTOR:
7.159CITATION COUNT:
68Perkins EJ, Ankley GT, Crofton KM, Garcia-Reyero N, Lalone CA, Johnson MS, Tietge JE, Villeneuve DL (2013) Current perspectives on the use of alternative species in human health and ecological hazard assessments.
Environmental Health Perspectives 121(9): 1002-1010.
DOI:
10.1289/ehp.1306638EID:
2-s2.0-84883283839PMID: 23771518
DOWNLOAD PDFABSTRACTBackground: Traditional animal toxicity tests can be time and resource intensive, thereby limiting the number of chemicals that can be comprehensively tested for potential hazards to humans and/or to the environment.Objective: We compared several types of data to demonstrate how alternative models can be used to inform both human and ecological risk assessment.Methods: We reviewed and compared data derived from high throughput in vitro assays to fish reproductive tests for seven chemicals. We investigated whether human-focused assays can be predictive of chemical hazards in the environment. We examined how conserved pathways enable the use of nonmammalian models, such as fathead minnow, zebrafish, and Xenopus laevis, to understand modes of action and to screen for chemical risks to humans.Results: We examined how dose-dependent responses of zebrafish embryos exposed to flusilazole can be extrapolated, using pathway point of departure data and reverse toxicokinetics, to obtain human oral dose hazard values that are similar to published mammalian chronic toxicity values for the chemical. We also examined how development/safety data for human health can be used to help assess potential risks of pharmaceuticals to nontarget species in the environment.Discussion: Using several examples, we demonstrate that pathway-based analysis of chemical effects provides new opportunities to use alternative models (nonmammalian species, in vitro tests) to support decision making while reducing animal use and associated costs.Conclusions: These analyses and examples demonstrate how alternative models can be used to reduce cost and animal use while being protective of both human and ecological health.Citation: Perkins EJ, Ankley GT, Crofton KM, Garcia-Reyero N, LaLone CA, Johnson MS, Tietge JE, Villeneuve DL. 2013. Current perspectives on the use of alternative species in human health and ecological hazard assessments. Environ Health Perspect 121:1002-1010; https://doi.org/10.1289/ehp.1306638.
The IGBB is supported, in part, by the following units:
The IGBB is an HPC² member center.
